ArticleStem cells translational medicine2017
Safety and Efficacy of Megakaryocytes Induced from Hematopoietic Stem Cells in Murine and Nonhuman Primate Models.
Article in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- A novel fusion protein of COVID-19 virus enhancing protection of Syrian hamsters infected with SARS-CoV-2.Acta pharmaceutica Sinica. B · 2026Article
- Why might cord blood be a better source of platelets for transfusion to neonates?Blood transfusion = Trasfusione del sangue · 2024Review
- Review
- Identification and characterization of a novel cell binding and cross-reactive region on spike protein of SARS-CoV-2.Scientific reports · 2022Article
- Ricolinostat promotes the generation of megakaryocyte progenitors from human hematopoietic stem and progenitor cells.Stem cell research & therapy · 2022Article
- Therapeutic use of red blood cells and platelets derived from human cord blood stem cells.Stem cells translational medicine · 2021Review
- Large-scale generation of megakaryocytes from human embryonic stem cells using transgene-free and stepwise defined suspension culture conditions.Cell proliferation · 2021Article
- Review
- Good Manufacturing Practice-Grade of Megakaryocytes Produced by a Novel Ex Vivo Culturing Platform.Clinical and translational science · 2020Article
- Safety and efficacy of ex vivo expanded CD34Stem cell research & therapy · 2019Article
- Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors.Scientific reports · 2018Article
- Evaluation of ex vivo produced endothelial progenitor cells for autologous transplantation in primates.Stem cell research & therapy · 2018Article
- Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34Stem cells translational medicine · 2017Article
- A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation.Stem cell research & therapy · 2017Article
- An effective ex-vivo approach for inducing endothelial progenitor cells from umbilical cord blood CD34Stem cell research & therapy · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because of a lack of platelet supply and a U.S. Food and Drug Administration-approved platelet growth factor, megakaryocytes have emerged as an effective substitute for alleviating thrombocytopenia. Here, we report the development of an efficient two-stage culture system that is free of stroma, animal components, and genetic manipulations for the production of functional megakaryocytes from hematopoietic stem cells. Safety and functional studies were performed in murine and nonhuman primate models. One human cryopreserved cord blood CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.